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cu.2012.Abstract Tamoxifen citrate (TC) and raloxifene hydrochloride (RH) are two selective estrogen
receptor modiﬁers. TC is usually used in the treatment of breast cancer while RH is used in the
treatment of osteoporosis. Two stability indicating methods, namely, ﬁrst derivative of ratio spectra
(1DD) and TLC-densitometric method are used for the determination of TC in the presence of its
photodegradants and RH in the presence of its oxidative degradants. For the ﬁrst derivative of ratio
spectra method, TC was quantitatively measured at 263 nm and 298.2 nm in a concentration range
of 10–60 lg/mL while RH was determined at 267.6 nm in a concentration range of 2–18 lg/mL. In
the spectro-densitometric method, TC was separated from its photodegradants using a developing
system consisting of acetonitrile: 33% ammonia solution (10: 0.1, v/v) in a concentration range of
6–20 lg/band while RH was separated from its oxidative degradants using ethyl acetate: methanol:
33% ammonia solution (7: 3: 0.1, by volume) as a developing system in a concentration range of 3–
11 lg/band. The two methods were successfully applied for the stability indicating the determina-
tion of the two drugs in a pure powdered form and a pharmaceutical dosage form and showing
good recoveries. Statistical comparison between the results obtained by applying the proposed
methods and the ofﬁcial method or the reported method for TC and RH, respectively was done
and no signiﬁcant difference was found at p= 0.05.
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70 H.A. Merey et al.1. Introduction
Tamoxifen citrate (TC) ((Z)-2-[4-(1,2-diphenyl-1-bute-
nyl)phenoxyl]-N,N-dimethyl-ethanamine-citrate) and raloxif-
ene hydrochloride (RH) ([6-hydroxy-2-(4-hydroxyphenyl) benzo
[b]hien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone hydro-
chloride) are synthetic estrogen level modiﬁers. These compounds
block estrogen action in the breast and uterus but also can main-
tain bone density and reduce circulating levels of cholesterol as
estrogen-like molecules.1 TC is a member of the triphenylethylene
antiestrogen group. It binds strongly to estrogen receptors leading
to the formation of complexes which are unable to translocate into
the nucleus of target tissues or do not bind properly to the accep-
tor site of chromatin.2 TC acts as a partial agonist exhibiting
antagonistic effects in breast tissues while giving agonistic effects
in the uterus and bones. RH is an example of the benzothiophene
selective estrogen receptor modulators. It maintains bone density
and is used for the treatment of osteoporosis.3 Reviewing the
literature, different analytical methods were used for the quantita-
tive determination of the cited drugs including high performance
liquid chromatography,4–13 electrochemical methods14–16 and
spectrophotometric methods.17–21 No stability indicating methods
were reported for the analysis of cited drugs, therefore, the aim of
this work was to develop simple accurate and precise methods for
the determination of both drugs in the presence of their
degradants.2. Experimental
2.1. Reagents
All chemicals used were of analytical grade and all solvents
were of spectroscopic or HPLC grade.
Methanol, 33% ammonia solution and ethyl acetate were
obtained from Prolabo (Pennsylvania, USA) while acetonitrile,
HPLC-grade, was obtained from E. Merck (Darmstadt,
Germany).
2.2. Pure samples
Tamoxifen citrate (TC) was kindly supplied by Sedico, 6th
October, Egypt. Its purity was found to be 99.88 ± 1.061
according to the ofﬁcial method22 while raloxifene hydrochlo-ride (RH) was kindly supplied by Lilly, Cairo, Egypt and its
purity was found to be 99.99 ± 1.150 according to the re-
ported method.23.
2.3. Market samples
 Nolvadex tablets, B. N. 70111, labeled to contain 10 mg of
tamoxifen, packed by AstraZeneca, Egypt under License of
AsraZeneca UK.
 Evista tablets B. N. A396125, labeled to contain 60 mg of
raloxifene hydrochloride, produced by Lilly S.A. Madrid,
Spain.2.4. Standard solutions
 Standard solutions were prepared by separately dissolving
TC and RH in methanol to obtain 1 mg/mL. Working
solutions were prepared by a suitable dilution of the standard
solution with methanol to obtain 0.1 mg/mL of both cited
drugs.
 Stock solution of TC photodegradants was derived from
exposing (0.8 mg/mL) pure TC to sunlight radiation for
23 h during July, at a temperature of 37 C± 2, from 8 am
to 4 pm for three days.Working solution of photodegradants
was prepared by a suitable dilution of the stock solution of
TC photodegradants with methanol to obtain 0.1 mg/mL.
 Standard solution of RH oxidative degradants was derived
from reﬂuxing 1 mg/mL of pure RH with 30% hydrogen
peroxide for 12 h. Working standard solution of oxidative
degradants was prepared by a suitable dilution of the stan-
dard solution of RH oxidative degradants with methanol to
obtain (0.2 mg/mL).2.5. Instruments
 Spectrophotometric measurements were done using a double
beamUV–Visible spectrophotometer (Shimadzu,Kyoto, Japan)
modelUV-1601 PC connected to an IBMcompatible computer,
with UVPC personal spectroscopy software version 3.7. The
absorption spectra were carried out using 1 cm quartz cells.
 Solubilization was done using Sonicator (Bandelin Sonorex,
Germany).
 Spectro-densitometric determination was done using
Camag TLC scanner 3 S/N 130319 with winCats software
Figure 1 Zero-order absorption spectra of tamoxifen citrate 30 lg/mL (––) and its photodegradants 24 lg/mL (. . .. . ..) in methanol.
Novel stability indicating methods for the determination of certain synthetic estrogen level modiﬁers 71after an application of spots on Precoated TLC-plates,
silica gel 60 G F254 (20 cm · 20 cm, 0.25 mm), E. Merck,
(Darmstadt-Germany) using Camag Linomat 5 autosam-
pler (Switzerland) with the aid of Camag microsyringe
(100 lL), Switzerland.Figure 2 Zero-order absorption spectra of raloxifene HCl (16 lg/mL
using methanol as blank.2.6. Procedures
2.6.1. Degradation of TC and RH
TC was subjected to photodegradation utilizing sunlight radi-
ation where a portion of the pure drug (20 mg) was accurately) (––) and its oxidative degradants equivalent to 20 lg/mL (. . .. . ..)
Figure 3 First derivative of the ratio spectra curves of tamoxifen citrate. 10–60 lg/mL (––) and of its photodegradants 20 lg/mL (. . ...)
using the spectrum of 24 lg/mL of photodegradants as divisor.
Table 1 Assay validation sheet of the proposed methods and parameters of the regression equations.
Parameters Tamoxifen citrate Raloxifene hydrochloride
(1DD) at 263 nm (1DD) at 298.2 nm TLC-densitometric (1DD) at 267.6 nm TLC-densitometric
Range 10–60 lg/mL 10–60 lg/mL 6–20 lg/band 2–18 lg/mL 3–11 lg/band
Slope 0.0247 0.0326 0.0048 0.1036 0.0316
Intercept 0.0353 0.0241 1.32 0.0079 1.2277
Mean 100.02 100.18 100.00 99.96 99.96
S.D. 0.738 0.937 0.608 0.904 1.264
Variance 0.545 0.878 0.370 0.817 1.598
Correlation coeﬃcient 0.9998 0.9998 0.9998 0.9999 0.9996
RSD(a) (0.476–0.618–1.186) (0.477–0.992–0.406) (0.622–0.519–0.705) (0.133–0.420–0.715) (0.661–1.120–0.781)
RSD(b) (0.993–0.971–0.806) (0.793–1.074–1.038) (0.799–0.919–0.863) (0.580–0.716–0.895) (1.036–1.695–1.397)
a The intraday and bthe interday relative standard deviations of different concentrations of TC (10, 30 and40 lg/mL) and RH (6, 10 and 14 lg/
mL) for the 1DD method, and (8, 10 and 14 lg/band) for TC and (4, 8 and 10 lg/band) for RH for the TLC-densitometric method.
72 H.A. Merey et al.transferred and dissolved in methanol in a 25-mL well ﬁtted
volumetric ﬂask. The ﬂask was left in sunlight, during July,
at a temperature of 37 C± 2, from 8 am to 4 pm for 3 days.
Complete degradation was assessed by TLC-fractionation on
silica gel 60 G F254 plates using acetonitrile: 33% ammonia
solution (10: 0.1, v/v) as developing solvent. Visualization
was carried out under UV-lamp at 254 nm.
RH was subjected to oxidative degradation using hydrogen
peroxide where 100 mg of the pure drug was dissolved in
100 mL methanol. 5 mL of 30% hydrogen peroxide was added
and the solution was reﬂuxed for 12 h. Complete degradation
was assessed by TLC-fractionation on silica gel F254 plates
using ethyl acetate:methanol:33% ammonia solution (7:3:0.1,
by volumes) as a developing solvent. Visualization was carried
out under UV-lamp at 254 nm.After complete degradation, the degraded solutions were
evaporated nearly to dryness then the residues were quantita-
tively redissolved in methanol.
2.6.2. First derivative of ratio spectra method
2.6.2.1. Linearity. Into a series of 10-mL volumetric ﬂasks, ali-
quots equivalent to 0.1–0.6 mg of TC or to 0.02–0.18 mg of
RH were accurately transferred from their working solution
(0.1 mg/mL). Each ﬂask was completed to the mark with
methanol. The spectra of the prepared standard solutions were
scanned (200–400 nm) and recorded. The stored spectra of TC
were divided (amplitude at each wavelength) by the spectrum
of 24 lg/mL of photodegradants and the spectra of RH were
divided by the spectrum of 24 lg/mL of oxidative degradants.
The ﬁrst derivative of the ratio spectra (1DD) was obtained at
Figure 4 First derivative of the ratio spectra of (2–18 lg/mL) raloxifene HCl (––) using the spectrum of 24 lg/mL of oxidative
degradants as divisor.
Table 2 Results of determination of tamoxifen citrate and raloxifene HCl in the presence of their degradants in laboratory prepared
mixtures by the suggested ﬁrst derivative of ratio spectra spectrophotometric method.
Mix. No Tamoxifen citrate Raloxifene HCl
TC degradants TC conc.
(lg/mL)
Recovery %* RH degradants RH conc.
(lg/mL)
Recovery %*
% (lg/mL) at 263 nm at 298.2 nm % (lg/mL)
1 17 10 50 100.76 100.32 11 2 16 100.19
2 33 20 40 101.10 101.15 22 4 14 100.29
3 50 30 30 101.33 102.10 44 8 10 100.40
4 67 40 20 98.05 100.45 66 12 6 98.33
5 83 50 10 115.60** 103.10** 88 16 2 115.00**
Mean ± SD 100.31 ± 1.525 101.01 ± 0.816 99.80 ± 0.985
RSD 1.520 0.808 0.987
* Average of three different determinations.
** Rejected values.
Novel stability indicating methods for the determination of certain synthetic estrogen level modiﬁers 73Dk= 4 and a scaling factor = 10 or at Dk= 4 and a scaling
factor = 100 for TC and RH, respectively. The amplitudes
of the ﬁrst derivative of the ratio spectra peak at 263 nm and
298.2 nm for TC or at 267.6 nm for RH. Calibration graph
was constructed relating the peak amplitudes of (1DD) to the
corresponding concentrations and then the regression equa-
tions were computed.
2.6.2.2. Analysis of pharmaceutical dosage form. Twenty
Nolvadex tablets or ten Evista tablets (after removing the
coat with methanol and stand for 5 min, to dry), were accu-
rately weighed and ﬁnely powdered. A quantity of the pow-dered tablets claimed to contain 10 mg of TC or RH was
weighed and transferred to a 100-mL volumetric ﬂask,
followed by 60 mL methanol and the mixture was sonicated
for one hour. The solution was ﬁltered and the residue was
washed with methanol 3 times then the volume was completed
with methanol. Analysis was done as mentioned under linear-
ity. The concentrations were calculated from the correspond-
ing regression equations.
2.6.3. TLC-densitometric method
2.6.3.1. Chromatographic condition. Analysis was performed on
precoated thin layer chromatographic plates, silica Gel 60 F254
Table 3 Results of determination of tamoxifen citrate in Nolvadex tablets and raloxifen HCl in Evista tablets by the proposed ﬁrst
derivative of ratio spectra spectrophotometric method and application of standard addition technique.
Pharmaceutical dosage forms Found %± SD* Claimed amount taken
(lg/mL)
Standard added
(lg/mL)
Recovery % of standard added*
at 263 nm at 298.2 nm at 263 nm at 298.2 nm
Nolvadex tablets B.N.70111 99.37 ± 0.629 99.70 ± 0.747 20.00 10.00 98.90 100.60
20.00 100.55 101.45
30.00 101.83 100.46
Mean ± SD 100.43 ± 1.469 100.84 ± 0.536
RSD 1.463 0.532
Evista coated tablets B.N.A396125 99.33 ± 0.707 6.00 4.00 99.00
6.00 100.17
8.00 100.25
Mean ± SD 99.81 ± 0.700
RSD 0.701
* Average of three different determinations.
74 H.A. Merey et al.(20 cm · 10 cm, 0.25 mm). Samples were applied on the plates
in the form of bands using Camag Linomat 5 autosampler uti-
lizing a 100 lL Camag micro-syringe. The band length was
3 mm and the dosage speed was 150 nL/S. Bands were applied
9.3 mm apart from each other and 10 mm from the bottom
edge of the plate. The nitrogen dried plates, were developed
in chromatographic tank, presaturated for at least one hour
with acetonitrile:33% ammonia solution (10:0.1, v/v) or ethyl-
acetate:methanol:33% ammonia solution (7:3:0.1, v/v) for TC
and its photodegradation or RH and its oxidative degradation,Figure 5 TLChromatogram of (a) tamoxifen citrate, (b) Deg. 2 and
ammonia) (10:0.1, v/v), silica gel 60 GF254 plates and scanning at 280respectively, to a distance of approximately 8 cm. The devel-
oped plates were air dried and scanned at the following instru-
mental conditions:
 Source of radiation: deuterium lamp.
 Scan mode: absorbance mode.
 Slit dimensions: 3 mm · 0.45 mm.
 Scanning speed: 20 mm/S.
 Result output: chromatogram and integrated peak area.
 Wave length: 280 or 288 nm for TC or RH, respectively.(c) Deg. 1, separated using developing solvent (acetonitrile:33 %
nm.
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Figure 6 Residuals plot for the calibration of tamoxifen citrate
using linear ﬁt (a) and polynomial ﬁt (b).
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(3–11 lg) of RH were applied from their stock solutions
(1 mg/mL) on thin layer chromatographic plates. The speciﬁed
chromatographic conditions were adopted, and calibration
curve was constructed by plotting areas under the peaks
(AUP) versus drug concentrations and the corresponding
regression equations were computed.
2.6.3.3. Analysis of pharmaceutical dosage form. Twenty
Nolvadex tablets or ten Evista tablets (after removing the
coat with methanol and stand for 5 min, to dry), were accu-
rately weighed and ﬁnely powdered. A quantity of the pow-
dered tablets claimed to contain 50 mg of TC or RH was
weighed and transferred to a 50-mL volumetric ﬂask, followed
by 30 mL methanol and the mixture was sonicated for one
hour. The solution was ﬁltered and the residue was washed
with methanol 3 times then the volume was completed with
methanol. Analysis was done as mentioned under linearity.
The concentrations were calculated from the corresponding
regression equations.
2.6.4. Methods validation
Method validation was performed according international
conference on harmonization ICH guidelines24 for the pro-
posed methods.
2.6.4.1. Accuracy. The previously mentioned procedure under
linearity was repeated for different concentrations of the pure
TC and RH samples to check the accuracy of the methods. The
concentrations were calculated from the corresponding regres-
sion equations and the mean percentage recoveries were then
estimated. The accuracy of the proposed methods was also val-
idated by applying the standard addition technique.
2.6.4.2. Precision. The previous procedure was repeated for the
analysis of samples of TC and RH three times on the same day
and on three successive days. The concentrations were calcu-
lated from the corresponding regression equations and the rela-
tive standard deviations (RSDs) were calculated and evaluated.
2.6.4.3. Speciﬁcity. Laboratory prepared mixtures containing
TC and different percentages of its photodegradants or of
RH and different percentages of its oxidative degradants were
prepared and analyzed by proper procedures and the percent-
age recoveries were calculated from the corresponding regres-
sion equations.
3. Results and discussion
3.1. Degradation of TC and RH
Literature survey on the stability of estrogen modiﬁers showed
that TC is liable to photodegradation while RH is liable to oxi-
dative degradation. Photodegradation of TC was studied by
Salamoun et al.25 and DellaGreca et al.26 Salamoun et al.25 re-
ported that during the UV irradiation of TC, isomerization of
the trans to the cis isomer takes place and consequently, corre-
sponding highly ﬂuorescent phenanthrene derivatives are
formed. The structures of photoproducts were identiﬁed
by HPLC, GC–MS, 1H NMR spectroscopy and LC-MS.
DellaGreca et al.26 studied the photodegradation of tamoxifenin water by prolonged exposure to sunlight irradiation. The
main photoproducts, have been identiﬁed by spectroscopic
means, where photoisomerization, photocyclization and, to a
lesser extent, photooxygenation appear to be involved in the
drug degradation.
In this work, the process of photodegradation was moni-
tored after exposing the drug to irradiation from sunlight,
where complete degradation took place after 23 h of exposure
to sunlight, at a temperature of 37 C± 2, from 8 am to 4 pm
for 3 days. The degradation process was monitored by TLC
using silica gel 60G F254 plates and acetonitrile: 33% ammonia
solution (10: 0.1, v/v) as developing solvent. Visualization of
the spots was done using UV-lamp at 254 nm where two new
spots appeared at Rf values 0.83 and zero for Degradant 1
and Degradant 2, respectively.
Oxidative degradation of RH was studied by Hartauer
et al27 which reported that RH was converted to the N-oxide
degradant upon oxidation with H2O2 when the drug is slurried
with 0.3% aqueous solution of H2O2 and kept for one week at
room temperature. Practically, upon reﬂuxing RH with 30%
H2O2, complete degradation was achieved after 12 h giving a
mixture of 2 degradants that were separated on silica gel
F254 plates using ethyl acetate:methanol:33% ammonia solu-
tion (7:3:0.1, by volume) as a developing solvent. Visualization
was carried out under UV-lamp at 254 nm. Rf was found to be
0.04 and 0.09 for ﬁrst and second degradants, respectively.
Since no stability indicating analytical methods were reported
for the determination of the cited drugs in the presence of their
degradation products, therefore, the aim of this work was to
Figure 7 TLChromatogram of (a) raloxifene HCl (Rf = 0.61), (b) its oxidative degradants Deg. 1 and Deg. 2 (Rf = 0.04 and 0.09) using
ethyl acetate:methanol:33% ammonia solution (7:3:0.1, by volumes) as a developing system.
Table 4 Results obtained for the determination of pure tamoxifen citrate in the presence of its photodegradants and raloxifene HCl in
the presence of its oxidative degradants by the suggested densitometric method.
Mixture No. Tamoxifen citrate Raloxifene HCl
Degradants % Taken
(lg/band)
Found
(lg/band)
Recovery
(%)*
Degradants % Taken
(lg/band)
Found
(lg/band)
Recovery
(%)*
1 14 12.00 12.09 100.75 10 9.00 8.97 99.67
2 30 10.00 9.98 99.80 30 7.00 6.96 99.43
3 43 8.00 8.05 100.63 50 5.00 4.99 99.80
4 57 6.00 5.99 99.83 70 3.00 2.98 99.33
Mean ± SD 100.25 ± 0.508 99.56 ± 0.216
RSD 0.507 0.217
* Average of three different determinations.
76 H.A. Merey et al.develop simple spectrophotometric and chromatographic stabil-
ity indicating methods for the determination of these drugs.
3.2. First derivative of ratio spectra spectrophotometric (1DD)
method
The zero-order spectra of the studied drugs and their degra-
dants show great overlap as shown in (Figs. 1 and 2). Deriva-
tive technique was tried to solve this overlapping and was
found to be unsuccessful, therefore, derivative ratio spectros-
copy was investigated to resolve this overlap.Different divisors, Dk, and scaling factor were tried to ob-
tain maximum sensitivity and lowest noise.
For tamoxifen citrate, the best divisor was found to be the
spectrum of 24 lg/mL degradants. The ﬁrst derivative of ratio
spectra was obtained at Dk= 4 and scaling factor = 100
(Fig. 3). This ﬁgure indicates that tamoxifen citrate can be deter-
mined at 263 nm and 298.2 nm. The regression equations were
computed (Table 1). The mean percentage recovery and the
standard deviation for analyzing pure samples of tamoxifen cit-
rate were calculated and found to be 100.02 ± 0.738 at 263 nm
and 100.18 ± 0.937 at 298.2 nm, respectively. These results
Novel stability indicating methods for the determination of certain synthetic estrogen level modiﬁers 77indicate that both wavelengths can be used for the analysis of
laboratory prepared mixtures and pharmaceutical dosage form.
For RH, the best divisor was found to be the spectrum of
24 lg/mL degradants. The ﬁrst derivative of ratio spectra
was obtained at Dk= 4 and scaling factor = 100. The peak
amplitude at 267.6 nm was used for the determination of
raloxifene HCl in the presence of its oxidative degradants
(Fig. 4). The mean percentage recovery and standard deviation
for analyzing pure samples of raloxifene HCl were calculated
and found to be 99.96 ± 0.904.
The proposed methods were successfully applied for the
determination of the studied drugs in the presence of up to
70% of its degradants (Table 2) and were also successfully ap-
plied for the analysis of these drugs in their pharmaceutical
dosage forms with satisfactory percentage recoveries as shown
in Table 3.
The validity of the proposed methods was assessed by
applying the standard addition technique to pharmaceutical
dosage forms, Table 3.
3.3. TLC-densitometric method
The availability of scanning of densitometry as a highly
efﬁcient quantitative tool for the separation and analysis of
several samples simultaneously was suggested for the determi-
nation of the cited drugs in the presence of their degradants.Table 5 Results of determination of tamoxifen citrate in Nolvadex
densitometric method and application of standard addition techniqu
Pharmaceutical dosage forms Found %± SD* Claim
taken
Nolvadex tablets B.N.70111 96.63 ± 1.125 8.00
Mean ± SD
RSD
Evista coated tablets B.N.A396125 101.38 ± 0.884 4.00
Mean ± SD
RSD
* Average of three different determinations.
Table 6 Statistical analysis of the results of the proposed methods
Parameters Tamoxifen citrate
(1DD) at
263 nm
(1DD) at
298.2 nm
TLC-densitomet
Mean 100.02 100.18 100.00
S.D. 0.738 0.937 0.608
Variance 0.545 0.878 0.370
n 6 6 8
Student’s t-test*** 0.258 (2.262)*** 0.498 (2.262)*** 0.262 (2.201)***
F value*** 2.07 (5.19)*** 1.28 (5.19)*** 3.04 (4.12)***
* The ofﬁcial method was non-aqueous titration.17
** The reported method was HPLC method.18
*** Figures in parenthesis are the theoretical t- and F-values at p= 0.05.Different solvent systems were tried for this purpose. For
TC and its photodegradation, satisfactory results were ob-
tained using a developing solvent composed of acetoni-
trile:33% ammonia (10:0.1, v/v). The Rf values obtained were
0.31, 0.83 and zero for tamoxifen citrate (Deg. 1) and (Deg.
2), respectively, as shown in Fig. 5. The linear ﬁt was plotted
to represent these data but poor correlation coefﬁcient was ob-
tained (r= 0.9933). By comparing residual plots for polyno-
mial and linear ﬁt we found that better results were obtained
upon using polynomial ﬁt (Fig. 6), therefore linear ﬁt was re-
jected. This case was observed by many authors who attributed
this non linearity to the scattering of light at the plate surface.
This scattering is highly dependent on the type of substrate,
measuring wavelength, measuring mode, molar absorptivity
and concentrations of the samples.28 Calibration curves in den-
sitometry generally comprise a pseudolinear region at low sam-
ple concentrations. In some instances the pseudolinear range is
adequate for analytical purposes, while in others no reasonable
linear range may exist.29 The polynomial relationship was
adopted between the area under the peak and the correspond-
ing concentration of TC. The mean percentage recovery and the
standard deviation for analyzing pure samples of TC were cal-
culated and found to be 100.00 ± 0.608.
For RH and its oxidative degradants, satisfactory results
were obtained by using a mobile phase composed of ethyl ace-
tate: methanol: 33% ammonia (7: 3: 0.1, by volumes). Intact tablets and raloxifen HCl in Evista tablets by the proposed
e.
ed amount
(lg/band)
Standard added (lg/band) Recovery % of
standard added*
6.00 98.90
8.00 100.50
10.00 101.30
101.27 ± 0.751
0.742
3.00 98.33
4.00 99.75
5.00 98.40
99.83 ± 0.800
0.810
and the ofﬁcial or reported method of TC and RH, respectively.
Raloxifene hydrochloride
ric Oﬃcial
method*
(1DD) at 267.6 nm TLC-densitometric Reported
method**
99.88 99.96 99.96 99.99
1.061 0.904 1.264 1.150
1.126 0.817 1.598 1.323
5 9 9 6
0.057 (2.160)*** 0.047(2.160)***
1.62 (3.69)*** 1.21 (4.82)***
78 H.A. Merey et al.RH showed a retention value of 0.61 while its two degradants
had Rf value 0.04 and 0.09, Fig. 7. Different concentrations of
pure samples were analyzed by the proposed densitometric
method and satisfactory recoveries were obtained
99.96 ± 1.264. Results in table 4 illustrate a good selectivity
of the proposed methods for the determination of the studied
drugs in the presence of its degradants. The mean percentage
recoveries were 100.25 ± 0.508 and 99.56 ± 0.216 for TC
and RH, respectively. The suggested methods were successfully
applied for the determination of TC and RH in their pharma-
ceutical formulations showing fair percentage recoveries equal
to 96.63 ± 1.125 and 101.38 ± 0.884 for TC and RH, respec-
tively, as shown in Table 5. The validity of the proposed meth-
od was assessed by applying the standard addition technique
to the pharmaceutical dosage form, Table 5.
The precision of the proposed derivative of ratio spectra
and TLC methods was expressed in terms of relative standard
deviation of the interday and intraday precision as shown in
Table 1.
3.4. Statistical analysis
Results obtained from the proposed methods were compared
to those obtained by applying the ofﬁcial non-aqueous titra-
tion method of TC or the reported HPLC of RH showing
no signiﬁcant difference as shown from the calculated t- and
F-values (Table 6).
4. Conclusion
The suggested methods were found to be simple, accurate,
selective and sensitive for the determination of TC and RH
in the presence of their degradants with no signiﬁcant differ-
ence between them and the ofﬁcial or reported methods and
therefore can be used for routine quality control of these
drugs.5. Conﬂict of interest
None.
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